A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
You can login here to your account or you can register to start saving, exploring and sharing resources and news. Connect with our community now!
Register to get the latest updates
Please join the RARE Portal to add diseases of interest to your personal profile. By creating a profile, you can receive news, resources and updates related to this disease as well as many other benefits.
Register to share with the community
You must be Corporate Alliance or Foundation Alliance member to contribute resources. Please contact us if you have a resource you’d like us to consider.
Contribute with resources
Alliance or Foundation Alliance member to contribute resources. Please contact us if you have a resource you’d like us to consider.
Be a Guest BLOGGER
Thank you for your interest in becoming in a guest blogger. Please email email@example.com for more information.